Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Aug 30:1:66-71.
doi: 10.1016/j.prdoa.2019.08.005. eCollection 2019.

Corticobasal degeneration and corticobasal syndrome: A review

Vasilios C Constantinides  1 , George P Paraskevas  1 , Panagiotis G Paraskevas  2 , Leonidas Stefanis  1 , Elisabeth Kapaki  1
Affiliations
Review

Corticobasal degeneration and corticobasal syndrome: A review

Vasilios C Constantinides et al. Clin Park Relat Disord. .

Abstract

Corticobasal degeneration (CBD) is a rare neurodegenerative disorder. The most common presentation of CBD is the corticobasal syndrome (CBS), which is a constellation of cortical and extrapyramidal symptoms and signs. Clinical-pathological studies have illustrated that CBD can present with diverse clinical phenotypes, including a non-fluent, agrammatic primary progressive aphasia syndrome, a behavioral, dysexecutive and visuospatial syndrome, as well as a progressive supranuclear palsy-like syndrome. Conversely, multiple pathologies, such as CBD, Alzheimer's disease and progressive supranuclear palsy may underlie a patient with CBS. This clinical-pathological overlap emphasizes the need for biomarkers that will assist in the accurate diagnosis of patients with CBS. This review presents an overview of the pathological, genetic, clinical and therapeutic characteristics of CBD, with an emphasis on the imaging (structural and functional) and biochemical (cerebrospinal fluid) biomarkers of CBD.

Keywords: Biomarkers; Cerebrospinal fluid; Corticobasal degeneration; Corticobasal syndrome; MRI; PET; Spect.

PubMed Disclaimer

Conflict of interest statement

The authors does not have any conflict of interest.

References

    1. Rebeiz J.J., Kolodny E.H., Richardson E.P., Jr. Corticodentatonigral degeneration with neuronal achromasia: a progressive disorder of late adult life. Trans. Am. Neurol. Assoc. 1967;92:23–26. - PubMed
    1. Gibb W.R., Luthert P.J., Marsden C.D. Corticobasal degeneration. Brain. 1989;112(Pt 5):1171–1192. - PubMed
    1. Dickson D.W., Bergeron C., Chin S.S. Office of Rare Diseases neuropathologic criteria for corticobasal degeneration. J. Neuropathol. Exp. Neurol. 2002;61(11):935–946. - PubMed
    1. Armstrong M.J., Litvan I., Lang A.E. Criteria for the diagnosis of corticobasal degeneration. Neurology. 2013;80(5):496–503. - PMC - PubMed
    1. Ling H., O'Sullivan S.S., Holton J.L. Does corticobasal degeneration exist? A clinicopathological re-evaluation. Brain. 2010;133(Pt 7):2045–2057. - PubMed

LinkOut - more resources